6. Clinical response rate assessed by RECIST v1.0 by cancer type in patients treated with fluzoparib.

Variables	Ovarian cancer	Breast cancer	Colorectal cancer	Gastric cancer and other tumor types	Total
RECIST, Response Evaluation Criteria in Solid Tumor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.
Total subjects	47	16	8	8	79
Efficacy evaluable subjects	37	13	8	7	65
CR	0	0	0	0	0
PR	3	1	0	0	4
SD	14	2	0	0	16
PD	20	10	8	7	45
ORR based on total subjects (%)	6.4	6.3	0	0	5.1
DCR based on total subjects (%)	36.2	18.8	0	0	25.3
ORR based on evaluable subjects (%)	8.1	7.7	0	0	6.2
DCR based on evaluable subjects (%)	45.9	23.1	0	0	30.8